Thr84
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.3
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Thr84  -  NCL (human)

Site Information
PAkkAAVtPGkkAAA   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 9765542

In vivo Characterization
Methods used to characterize site in vivo:
immunoprecipitation ( 1 ) , mass spectrometry ( 2 , 3 , 4 , 6 , 8 , 9 , 10 , 11 , 12 , 13 , 14 , 15 , 16 ) , phospho-antibody ( 1 ) , western blotting ( 1 )
Disease tissue studied:
bladder cancer ( 1 ) , breast cancer ( 4 ) , breast ductal carcinoma ( 4 ) , HER2 positive breast cancer ( 2 ) , luminal A breast cancer ( 2 ) , luminal B breast cancer ( 2 ) , breast cancer, surrounding tissue ( 2 ) , breast cancer, triple negative ( 2 , 4 ) , cervical cancer ( 12 ) , cervical adenocarcinoma ( 12 ) , acute erythroid leukemias, including erythroleukemia (M6a) and very rare pure erythroid leukemia (M6b) ( 6 ) , acute megakaryoblastic leukemia (M7) ( 6 ) , acute monoblastic leukemia (M5a) or acute monocytic leukemia (M5b) ( 6 ) , acute myeloblastic leukemia, with granulocytic maturation (M2) ( 6 ) , hepatocellular carcinoma, surrounding tissue ( 14 ) , lung cancer ( 15 , 16 ) , non-small cell lung cancer ( 15 , 16 ) , ovarian cancer ( 4 )
Relevant cell line - cell type - tissue:
AML-193 (monocyte) ( 6 ) , breast ( 2 , 4 ) , CMK (megakaryoblast) ( 6 ) , HEL (erythroid) ( 6 ) , HeLa (cervical) ( 3 , 13 ) , HeLa S3 (cervical) [PLK1 (human), knockdown, Tet-inducible PLK1 siRNA] ( 10 ) , HeLa S3 (cervical) ( 10 , 12 ) , HeLa_Meta (cervical) ( 11 ) , HeLa_Pro (cervical) ( 11 ) , HeLa_Telo (cervical) ( 11 ) , hepatic-'liver, para-hepatocellular carcinoma tissue' ( 14 ) , Jurkat (T lymphocyte) ( 9 ) , Kasumi-1 (myeloid) ( 6 ) , KG-1 (myeloid) ( 6 ) , lung ( 15 , 16 ) , MV4-11 (macrophage) ( 6 ) , ovary ( 4 ) , P31/FUJ (erythroid) ( 6 ) , UMUC3 (bladder cell) ( 1 )

Upstream Regulation
Treatments:
MG132_withdrawal ( 11 ) , nocodazole ( 12 ) , ZK-Thiazolidinone ( 10 )

Downstream Regulation
Effects of modification on NCL:
molecular association, regulation ( 1 )
Effects of modification on biological processes:
cell growth, induced ( 1 )
Induce interaction with:
DDX31 (human) ( 1 )

References 

1

Daizumoto K, et al. (2018) A DDX31/mutant-p53/EGFR axis promotes multistep progression of muscle invasive bladder cancer. Cancer Res
29440146   Curated Info

2

Mertins P, et al. (2016) Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534, 55-62
27251275   Curated Info

3

Sharma K, et al. (2014) Ultradeep human phosphoproteome reveals a distinct regulatory nature of Tyr and Ser/Thr-based signaling. Cell Rep 8, 1583-94
25159151   Curated Info

4

Mertins P, et al. (2014) Ischemia in tumors induces early and sustained phosphorylation changes in stress kinase pathways but does not affect global protein levels. Mol Cell Proteomics 13, 1690-704
24719451   Curated Info

5

Shiromizu T, et al. (2013) Identification of missing proteins in the neXtProt database and unregistered phosphopeptides in the PhosphoSitePlus database as part of the Chromosome-centric Human Proteome Project. J Proteome Res 12, 2414-21
23312004   Curated Info

6

Casado P, et al. (2013) Phosphoproteomics data classify hematological cancer cell lines according to tumor type and sensitivity to kinase inhibitors. Genome Biol 14, R37
23628362   Curated Info

7

Beli P, et al. (2012) Proteomic Investigations Reveal a Role for RNA Processing Factor THRAP3 in the DNA Damage Response. Mol Cell 46, 212-25
22424773   Curated Info

8

Rikova K (2012) CST Curation Set: 13916; Year: 2012; Biosample/Treatment: cell line, Mix of TMT treated cell lines 2/treated; Disease: -; SILAC: -;
Curated Info

9

Guo A (2011) CST Curation Set: 12436; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

10

Santamaria A, et al. (2011) The Plk1-dependent phosphoproteome of the early mitotic spindle. Mol Cell Proteomics 10, M110.004457
20860994   Curated Info

11

Dulla K, et al. (2010) Quantitative site-specific phosphorylation dynamics of human protein kinases during mitotic progression. Mol Cell Proteomics 9, 1167-81
20097925   Curated Info

12

Olsen JV, et al. (2010) Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis. Sci Signal 3, ra3
20068231   Curated Info

13

Pan C, Olsen JV, Daub H, Mann M (2009) Global effects of kinase inhibitors on signaling networks revealed by quantitative phosphoproteomics. Mol Cell Proteomics 8, 2796-808
19651622   Curated Info

14

Gu T (2009) CST Curation Set: 7555; Year: 2009; Biosample/Treatment: liver, para-hepatocellular carcinoma tissue, hepatic/untreated; Disease: liver cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

15

Rikova K (2009) CST Curation Set: 6618; Year: 2009; Biosample/Treatment: tissue, lung/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

16

Rikova K (2008) CST Curation Set: 4076; Year: 2008; Biosample/Treatment: tissue, lung/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info